NL-OMON41699已完成不适用
Factors influencing the outcome of nilotinib treatment in patients with chronic myeloid leukemia in daily practice - Response and Adherence to Nilotinib in Daily practice (RAND-study)
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 70
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •- Male or female patients >= 18 years of age
- •- ECOG 0, 1, or 2.
- •- Diagnosis of chronic myelogenous leukemia with cytogenetic confirmation of Philadelphia chromosome of (9;22) translocations.
- •- Treatment with nilotinib.
排除标准
- •- Inability to grant consent.
研究者
相似试验
进行中（未招募）
1 期
Treatment for patients whith graft-versus-host disease after bone marrow transplantation.Chronic graft-versus-host disease .MedDRA version: 14.1Level: LLTClassification code 10008907Term: Chronic GVH diseaseSystem Organ Class: 100000004870EUCTR2012-000770-36-BECHU-ULg5
尚未招募
不适用
Efficacy and safety evaluation of nilotinib as primary treatment in newly diagnosed Philadelphia chromosome positive(Ph+) chronic myeloid leukemia(CML) patientsDiseases of the blood and blood -forming organs and certain disorders involving the immune mechanismKCT0000615Seoul National University Hospital114
招募中
2 期
Clinical study evaluating efficacy of Nilotinib in CML patientsChronic myelogenous leukemiaJPRN-UMIN000002579ara Hospital Kinki University School Of Medicine20
进行中（未招募）
1 期
A Phase II Trial of Nilotinib in the Treatment of Patients with c-KIT Mutated Advanced Acral and Mucosal Melanoma (NICAM) - Nilotinib in the Treatment of c-KIT Mutated Melanoma (NICAM)c-KIT mutated advanced acral or mucosal melanomaMedDRA version: 10 Level: LLT Classification code 10025654 Term: Malignant melanoma of sites other than skinMedDRA version: 10 Level: LLT Classification code 10000583 Term: Acral lentiginous melanomaEUCTR2009-012945-49-GBRoyal Marsden Hosptial Foundation Trust29
已完成
不适用
Prognostic and predictive factors of lenvatinib in patients with hepatocellular carcinomahepatocellular carcinomaJPRN-UMIN000036625Kitasato University Hospital100